[Featured Stock] Dongwha Pharm Highlights Stake in BB Biotech... 'Strong Rise'

[Asia Economy Reporter Yoo Hyun-seok] Dongwha Pharm is showing strong performance. It appears to be influenced by the news that SysWok was acquired by VBV, which jointly developed the COVID-19 antigen test kit with Celltrion, resulting in a limit-up price.

As of 1:36 PM on the 24th, Dongwha Pharm was trading at 22,900 KRW, up 5.77% (1,250 KRW) compared to the previous trading day.

Dongwha Pharm has actively invested in various bio venture companies. It has invested in various healthcare venture companies such as Vuno, aesthetic bio company Zetema, mobile healthcare company Philosys, healthcare, VBV, medical device manufacturer LivesMed, crowdfunding platform Crowdy, and accelerator Krypton. According to Dongwha Pharm's semi-annual report this year, the company holds a 3.2% (71,051 shares) stake in VBV.

VBV is a company that jointly developed the COVID-19 antigen test kit with Celltrion.

Meanwhile, on the 19th, Dongwha Pharm announced that it submitted a clinical phase 2 trial plan (IND) for the COVID-19 treatment 'DW2008S' to the Ministry of Food and Drug Safety. DW2008 is a new drug that Dongwha Pharm is developing as an asthma treatment.

This content was produced with the assistance of AI translation services.